Drug discovery and development group Redx Pharma has appointed its new chief executive officer in the form of Lisa Anson.
Anson, who was previously AstraZeneca’s UK president since 2012, also joins Redx’s board of directors, taking up both roles on 1 June.
With a 20-year career with AstraZeneca, Anson has held a variety of senior management roles at the pharmaceutical company, situated in both the US and UK, including global vice president oncology, and vice president of emerging brands, working closely with the research and development teams.
Ian Ross, executive chairman of Redx, said: “Lisa has been tasked by the board to lead the re-launch of the company and to take the steps necessary to build a substantial biotech company built upon an innovative science base, selectively acquiring additional assets.
“Lisa is a consummate business professional, who brings a wealth of relevant experience from the international pharmaceutical and biotech sector and I am confident that she is the right person to grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.”